Therasis gains $12M Series A cash

A start-up biotech company with deep scientific roots in New York has garnered $12 million to get to work on a cancer platform. Therasis raised the Series A cash from Tilocor Life Science. The developer has three key scientific founders: Dr. Andrea Califano, director of the Joint Centers for Systems Biology at Columbia University and associate director of the Herbert Irving Comprehensive Cancer Center; Riccardo Dalla-Favera, M.D., director of the Herbert Irving Comprehensive Cancer Center; and Owen A. O'Connor, M.D., Ph.D., presently deputy director of clinical research and cancer treatment at the New York University Cancer Institute. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.